[News] Nivolumab plus ipilimumab in advanced renal-cell carcinoma

The results of the CheckMate 214 study have shown that treatment with nivolumab plus ipilimumab in patients with advanced renal-cell carcinoma can improve outcomes compared with the current standard of care, sunitinib.

Source: The Lancet Oncology - March 29, 2018 Category: Cancer & Oncology Authors: Ashray Gunjur Tags: News Source Type: research